Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment
Background. Alkylresorcinols (ARs) are polyphenolic compounds of microbial origin with a wide spectrum of biological activities and are potentially involved in host immune functioning. The present study is aimed at evaluating alterations in AR content in blood serum and faeces from healthy donors an...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Advanced Gut & Microbiome Research |
| Online Access: | http://dx.doi.org/10.1155/2023/2333767 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558605462667264 |
|---|---|
| author | Aleksandr V. Shestopalov Oleg I. Kit Anastasia A. Zabolotneva Elena Y. Zlatnik Aleksey Yu Maksimov Inna A. Novikova Alexander B. Sagakyants Sofya V. Timofeeva Anna S. Goncharova Anastasia V. Galina Svetlana A. Appolonova Pavel A. Markin Valentin V. Makarov Sergey M. Yudin Anton A. Keskinov Sergei A. Roumiantsev Oleg I. Meshkov |
| author_facet | Aleksandr V. Shestopalov Oleg I. Kit Anastasia A. Zabolotneva Elena Y. Zlatnik Aleksey Yu Maksimov Inna A. Novikova Alexander B. Sagakyants Sofya V. Timofeeva Anna S. Goncharova Anastasia V. Galina Svetlana A. Appolonova Pavel A. Markin Valentin V. Makarov Sergey M. Yudin Anton A. Keskinov Sergei A. Roumiantsev Oleg I. Meshkov |
| author_sort | Aleksandr V. Shestopalov |
| collection | DOAJ |
| description | Background. Alkylresorcinols (ARs) are polyphenolic compounds of microbial origin with a wide spectrum of biological activities and are potentially involved in host immune functioning. The present study is aimed at evaluating alterations in AR content in blood serum and faeces from healthy donors and patients with lung cancer in connection with response to immune checkpoint inhibitor (ICI) therapy to estimate the regulatory potential of AR. Methods. Quantitative analysis of AR levels, as well as other microbial metabolites in blood serum and faeces, was performed using gas chromatography with mass spectrometric detection; estimation of lymphocyte subsets was performed by flow cytometry; faecal microbiota transplantation (FMT) from lung cancer patients after ICI therapy to germ-free mice was performed to explore whether the intestinal microbiota could produce AR molecules. Results. AR concentrations in both faeces and serum differ dramatically between healthy and lung cancer donors. The significant increase in AR concentrations in mouse faeces after FMT points to the microbial origin of ARs. For several ARs, there were strong positive and negative correlations in both faeces and serum with immune cells and these interrelationships differed between the therapy-responsive and nonresponsive groups. Conclusions. The content of ARs may influence the response to ICI therapy in lung cancer patients. ARs may be considered regulatory molecules that determine the functioning of antitumor immunity. |
| format | Article |
| id | doaj-art-8b2cdd81a5ab46e097fd3fe45df3eefd |
| institution | Kabale University |
| issn | 2755-1652 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Gut & Microbiome Research |
| spelling | doaj-art-8b2cdd81a5ab46e097fd3fe45df3eefd2025-02-03T01:32:00ZengWileyAdvanced Gut & Microbiome Research2755-16522023-01-01202310.1155/2023/2333767Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer TreatmentAleksandr V. Shestopalov0Oleg I. Kit1Anastasia A. Zabolotneva2Elena Y. Zlatnik3Aleksey Yu Maksimov4Inna A. Novikova5Alexander B. Sagakyants6Sofya V. Timofeeva7Anna S. Goncharova8Anastasia V. Galina9Svetlana A. Appolonova10Pavel A. Markin11Valentin V. Makarov12Sergey M. Yudin13Anton A. Keskinov14Sergei A. Roumiantsev15Oleg I. Meshkov16N. I. Pirogov Russian National Research Medical UniversityNational Medical Research Centre for OncologyN. I. Pirogov Russian National Research Medical UniversityNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologySechenov First Moscow State Medical UniversitySechenov First Moscow State Medical UniversityCenter for Strategic Planning and Management of Medical and Biological Health Risks of FMBA of RussiaCenter for Strategic Planning and Management of Medical and Biological Health Risks of FMBA of RussiaCenter for Strategic Planning and Management of Medical and Biological Health Risks of FMBA of RussiaN. I. Pirogov Russian National Research Medical UniversityCenter for Strategic Planning and Management of Medical and Biological Health Risks of FMBA of RussiaBackground. Alkylresorcinols (ARs) are polyphenolic compounds of microbial origin with a wide spectrum of biological activities and are potentially involved in host immune functioning. The present study is aimed at evaluating alterations in AR content in blood serum and faeces from healthy donors and patients with lung cancer in connection with response to immune checkpoint inhibitor (ICI) therapy to estimate the regulatory potential of AR. Methods. Quantitative analysis of AR levels, as well as other microbial metabolites in blood serum and faeces, was performed using gas chromatography with mass spectrometric detection; estimation of lymphocyte subsets was performed by flow cytometry; faecal microbiota transplantation (FMT) from lung cancer patients after ICI therapy to germ-free mice was performed to explore whether the intestinal microbiota could produce AR molecules. Results. AR concentrations in both faeces and serum differ dramatically between healthy and lung cancer donors. The significant increase in AR concentrations in mouse faeces after FMT points to the microbial origin of ARs. For several ARs, there were strong positive and negative correlations in both faeces and serum with immune cells and these interrelationships differed between the therapy-responsive and nonresponsive groups. Conclusions. The content of ARs may influence the response to ICI therapy in lung cancer patients. ARs may be considered regulatory molecules that determine the functioning of antitumor immunity.http://dx.doi.org/10.1155/2023/2333767 |
| spellingShingle | Aleksandr V. Shestopalov Oleg I. Kit Anastasia A. Zabolotneva Elena Y. Zlatnik Aleksey Yu Maksimov Inna A. Novikova Alexander B. Sagakyants Sofya V. Timofeeva Anna S. Goncharova Anastasia V. Galina Svetlana A. Appolonova Pavel A. Markin Valentin V. Makarov Sergey M. Yudin Anton A. Keskinov Sergei A. Roumiantsev Oleg I. Meshkov Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment Advanced Gut & Microbiome Research |
| title | Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment |
| title_full | Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment |
| title_fullStr | Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment |
| title_full_unstemmed | Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment |
| title_short | Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment |
| title_sort | alkylresorcinols as a new type of gut microbiota regulators influencing immune therapy efficiency in lung cancer treatment |
| url | http://dx.doi.org/10.1155/2023/2333767 |
| work_keys_str_mv | AT aleksandrvshestopalov alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT olegikit alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT anastasiaazabolotneva alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT elenayzlatnik alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT alekseyyumaksimov alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT innaanovikova alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT alexanderbsagakyants alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT sofyavtimofeeva alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT annasgoncharova alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT anastasiavgalina alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT svetlanaaappolonova alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT pavelamarkin alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT valentinvmakarov alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT sergeymyudin alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT antonakeskinov alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT sergeiaroumiantsev alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment AT olegimeshkov alkylresorcinolsasanewtypeofgutmicrobiotaregulatorsinfluencingimmunetherapyefficiencyinlungcancertreatment |